Syncom Formulations Reports Strong Q1 FY2026 YoY Growth in Revenue and Profit
The announcement of quarterly financial results is a regular disclosure, but the strong year-on-year growth in key financial metrics makes it a moderately impactful update for investors.
The company reported significant year-on-year growth in both standalone and consolidated revenue from operations and profit after tax for the quarter ended 30th June 2025.
Syncom Formulations (India) Limited announced its unaudited standalone and consolidated financial results for the quarter ended 30th June, 2025, approved by its Board of Directors on 8th August, 2025.
* Standalone Financial Highlights (Q1 FY2026 vs Q1 FY2025): * Revenue from Operations increased by 34.23% to ₹116.55 crore (₹11,654.69 Lakhs) from ₹86.83 crore (₹8,683.09 Lakhs). * Profit After Tax (PAT) surged by 106.16% to ₹15.73 crore (₹1,572.93 Lakhs) from ₹7.63 crore (₹762.86 Lakhs). * Basic Earnings Per Share (EPS) rose to ₹0.21 from ₹0.11.
* Consolidated Financial Highlights (Q1 FY2026 vs Q1 FY2025): * Revenue from Operations grew by 33.97% to ₹116.90 crore (₹11,690.17 Lakhs) from ₹87.26 crore (₹8,725.54 Lakhs). * Profit After Tax (PAT) increased by 106.41% to ₹15.75 crore (₹1,575.44 Lakhs) from ₹7.63 crore (₹763.25 Lakhs). * Basic Earnings Per Share (EPS) stood at ₹0.21, up from ₹0.11.
* Segment-wise Revenue (Consolidated, Q1 FY2026): * Pharmaceuticals Drugs & Formulations contributed ₹120.63 crore (₹12,062.52 Lakhs). * Trading of Commodities contributed ₹1.05 crore (₹104.56 Lakhs). * Renting of Property contributed ₹0.90 crore (₹89.58 Lakhs).
The results have been prepared in compliance with Indian Accounting Standards (Ind AS) and were subject to a limited review by the Statutory Auditors, which had no impact on the reported figures.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.